Continuing progress in radioimmunotherapy for hematologic malignancies.

Area of Science:

• Oncology
• Nuclear Medicine
• Immunotherapy

Background:

• Radioimmunotherapy (RIT) combines cytotoxic radionuclides with tumor-targeting antibodies to enhance therapeutic efficacy and reduce toxicity.
• Current RIT approaches, particularly beta-particle RIT targeting CD20, show effectiveness but face challenges in widespread adoption due to emerging therapies.

Purpose of the Study:

• To review current advancements and future prospects of RIT for hematologic malignancies.
• To explore novel RIT strategies aimed at improving tumor penetration and minimizing off-target radiation exposure.

Main Methods:

• Comprehensive review of recent investigations and clinical data on RIT for hematologic malignancies.
• Analysis of emerging RIT modalities including single-domain antibodies, alpha-particle RIT, and pretargeted radioimmunotherapy (PRIT).

Main Results:

• Beta-particle RIT targeting CD20 is effective for specific non-Hodgkin's lymphomas but has limited uptake.
• Single-domain antibodies in RIT may enhance tumor penetration and reduce radiation exposure to normal tissues.
• Alpha-particle RIT exhibits significant antitumor activity and reduced bystander effects due to high linear energy transfer.
• PRIT has the potential to improve the tumor-to-whole body dose ratio.

Conclusions:

• RIT remains a promising therapeutic strategy for hematologic malignancies, with ongoing developments enhancing its potential.
• Alpha-particle RIT and PRIT represent key advancements offering improved efficacy and safety profiles.
• Future RIT strategies focus on optimizing antibody design and targeting mechanisms for better clinical outcomes.